IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties
Abstract
Despite promising clinical trials, intravenous immunoglobulin (IVIg) therapy in relapsing–remitting multiple sclerosis (MS) has met with uncertainties that might be attributed to small patient cohorts, heterogeneity in the patients, dose of IVIg, or the duration and window of treatment.
Domains
Immunotherapy
Origin : Files produced by the author(s)
Loading...